Welcome, gentlemen.
Thank you.
Yeah. Thank you, Roger. Great to be here.
Thank you.
Awesome. All right. I think you have a major update and upcoming. Before we talk about that, maybe just take a step back. Where's the MBX coming from, and then what's the state of the union right now? Then we can talk about all the exciting things going to happen in the coming weeks.
Sure. Thanks, Roger. Thanks for the invitation to join for the conference. Sam and I are delighted to be here, great to be here, and every year, and to see the wide group of folks here that join for Jefferies. It's been a really transformative year for the company. If you go back to the May time point, early this summer, that was when we reported out, as you'll remember
the first blinded clinical data for MBX 4291, which is our GLP-1/GIP co-agonist for the treatment of patients with obesity. This was blinded data, which showed the initial disclosure associated with the program, which showed for the first time the ability in patients to dose a co-agonist on a once-monthly basis. Very encouraging data. It's been the source, of course, of a lot of attention for the company since that time. As you alluded to, we're coming up to a really important readout here, unblinding of data from that phase I/IIa study.
Later that summer, in addition, we also reported 12-month open-label extension data for our lead program canvuparatide, which is a replacement parathyroid hormone for patients with chronic hypoparathyroidism, showing sustained clinical benefit at that one-year time point for patients with chronic HP. This, of course, builds on the data, the phase II Avail data that we reported the prior year.
It's been a really exciting year of development and execution across the portfolio. We're really excited as we come into the rest of the year here, entering the last part of Q4, where the most important milestone for us, of course, is, as I said, that unblinded data for 4291.
Yeah. Excellent. All right. Fourth quarter, we are right in the middle, and then basically, that's why I say in the coming weeks, if not days. That is the cohort C1, and then it's unblinded 12-week with a four-weekly dose, and then a two-monthly dose. I think you probably guided, or at least set the expectation, 6%-8% placebo-adjusted weight loss. We did the research, and we think we agree with that in terms of the benchmark. But just to, let's put that into the context. This is the current drug or pipeline drug have been showing how this 6%-8% will be competitive in the future landscape, because we know MBX has tried to do longer-acting monthly dosing, and then maybe also put that combined with the tolerability as well.
Yeah. Thanks for the question, Roger. It's the right question and one that we get frequently from investors who are trying to understand what the right set of expectations is for the unblinded data. You're exactly right. There are three pillars, first of all, to the target product profile that we're trying to achieve, and the first of those is competitive weight lowering. As we think about the benchmark, and fortunately in this market, there are ample phase III studies to point to, what we see from the competitive set, whether it's tirzepatide or semaglutide, at the 12-week time point is between 6% and 8% weight lowering. We continue to believe that a competitive profile has to meet that expectation of a 6%-8% weight lowering at 12 weeks.
We'll see as we get to the unblind how we deliver on that key component of the TPP. The second component of the TPP is about improved tolerability, and this has been elusive in the field, and the reason I think it's been elusive for other monoagonists or co-agonists has all tracked back to, or traced back to PK, right? We know that all of the currently available agents, in fact, all of them, all of the agents in development, have a burst effect, so a rapid rise to Cmax, and that rapid rise to Cmax is what is linked to GI intolerance specifically. MBX 4291 was engineered using our prodrug technology to have a slow rise to Cmax, so it's five to six days to get to Cmax concentration.
What we saw in the blinded dataset that I referred to earlier, that we disclosed in May, what we saw in that dataset, even though it was blinded, six on active, two on placebo, was only one case of mild diarrhea. We are encouraged by the early data, but if we think about the disclosure coming up here in Q4, continuing to deliver on improved tolerability, we think is an important component also of the TPP. Lastly, it is about once-monthly dosing. We think the PK that we showed back in May will be confirmed in the larger dataset. I will remind you that we have in cohort C1 a total of 30 subjects, 20 who are on active, 10 on placebo, and we continue to expect to see confirmed a T-half Cmax of 26 days in that cohort C1, enabling true once-monthly dosing.
On its own, that component of the TPP is fundamentally unique in this landscape. There is no other monoagonist or co-agonist that has demonstrated the ability to be dosed once monthly. We are looking forward to the upcoming disclosure and addressing those three components of the TPP. Part of your question related to a changing landscape in obesity and what that future landscape may look like. We believe that a co-agonist weekly injectable is very likely to continue to be the mainstay of treatment for the vast majority of patients out there with obesity.
Is there a role potentially for triple G in morbidly obese patients? Absolutely. We believe that to be the case. There is clearly a segment of people who would benefit from either more rapid or ultimately more profound weight lowering. That clearly will have a place in the treatment armamentarium. Generally speaking, we think that a GLP-1/GIP co-agonist will remain the workhorse, if you will, of obesity treatment.
Got it. Okay. All right. We got the expectation, we got a benchmark. Of course, we always want to push a little bit and see what the upside can look like. When we look at the blinded data, right, it is already get there 6%-8% if it is not higher, blinded, we do not know which one is placebo-adjusted number. Then we look at the constant in looking at the exposure levels, right? So you are probably at the high end of the tirzepatide. Then the potency-wise, also is reaching the tirzepatide level. How should we think about how likely you are going to break that 8%, maybe get to the double digit? What will be the possible scenario for the weight loss on the placebo-adjusted base?
As you mentioned, when we disclosed the blinded data from cohort B1 back in May, you are right, we showed an aggregate pool data, blinded, the six active, two placebo. We showed already a 7% weight lowering at that earlier time point. That is the reason for your question, right? That was very encouraging. I think ultimately we will see in a broader data set, what the weight lowering looks like in C1 at the dose and schedule that we are studying in that cohort. But there is certainly a mechanistic reason to believe that the differentiated PK profile may in fact translate into a differentiated PD profile.
Not only in terms of the slow rise to Cmax resulting in potentially improved tolerability, but that this infusion-like PK that we can deliver with 4291, over the monthly period, may potentially deliver a differentiated weight lowering. It is hypothesis at this point, and we have limited and early blinded data that guides us, but we are looking forward to unblinded data and a larger group of patients, which ultimately those data, the totality of what we learn from this phase I/IIa study, I think will ultimately inform how we should think about the potential for 4291 to deliver on that TPP or even exceed that TPP.
Right. I listen very carefully. I want to make sure I'm not over-interpret that. You say you are guided by the blinded data. That blinded data is from C1 or it's from your previous B1?
Oh, the B1 data. Right.
That's the one I should-
Back in May.
Okay.
The blinded data, which is all that we have to go on, right, is that aggregated weight lowering data, the aggregated safety data. The PK, of course, is obvious, right?
Yeah.
That is clearly in patients receiving drug. But that is what we have to go on collectively. When we get to the unblind, as I said, we will see the data in the 30 subjects and have a better understanding of the profile.
Have you taken a look at the blinded data from the C1, either on the weight loss side or the tolerability side? Anything you can say now? First of all, have you looked at it? And then two is, anything you can comment on?
Well, very clearly from a GCP perspective, to manage and ensure patient safety on an ongoing clinical study, we of course have to have members of the team who monitor the data for safety reasons, as I said, to ensure patient safety.
However, when we get to the full unblinded data set, what we will have and what we will be able to show is, of course, weight lowering at that 12-week time point. We will be able to understand what the cadence or trajectory is of the weight lowering out to that 12-week time point, so looking at earlier time points as well. We will of course understand the tolerability, both in the placebo patients, but also importantly in the active patients, and we intend to look at that longitudinally. So to understand over time, what does the GI tolerability look like for patients? And this is important and relevant, as you know, because patients treated with this class of agents, when dose is titrated or stepped up, that tends to trigger additional GI intolerance. So understanding that trajectory of tolerability will be important.
The third component, of course, is the PK data. So that will all be, when it is unblinded, that will be the data that we are going to disclose, and as I said, help us to understand the profile of 4291, and then guide us into the next clinical development step.
We are working, as we speak, to prepare to initiate, assuming success, a phase II-B study next year. And in that study, we would expect that we are going to be testing not one, but probably multiple doses and schedules, all informed by the unblinded data, and that study would then generate additional information that will help to guide us as we think about a potential future phase III study.
Okay, good. Since we are on that topic in terms of the next step, based on, because this is C1, right? We know you have a C2 and then potentially can C3. Do you think with the C1 data, you will have enough information to move into the phase II, or you want to run something else before you can make the decision moving to the phase II?
Thanks, Roger. I think that the end of this phase I, we call it phase IIa, because we are in the target population of patients with BMI at or above 30. We will have enough information with the totality of evidence coming from this study to move to phase II.
Okay. Good. I believe you already started the C2. What are you going to learn from C2, and then when or if you will release the data?
Yeah, we disclosed and talked about part C of the study back in May, in fact. These two cohorts, C1 and C2, are not running exactly concurrently. There is a little bit of a stagger in terms of when C2 was started. But those data, of course, also will be informative as we think about the phase II design that Sam was just speaking about. When we get to our disclosure, coming up later in the quarter, Sam, I am sure, will be able to add some additional color on potential future data flow, what we will learn from the rest of the study, how we think about the phase II, all to set us up for future development steps.
Okay, got it. I got those. Probably you got a question as well, is the injection volume, right? Now the top dose is 180. Can you just comment on the concentration, how likely this can be delivered within one injection versus multiple, and then how much work you need to do in order to achieve that?
Yeah. Our focus is on, of course, preparing for that phase III study and making sure that we have a very commercially competitive presentation, drug device combination for that phase III study. We have high confidence that we will be able to deliver that in a single injection and in a device. That is work that is ongoing right now. In fact, as we did for canvuparatide, and as you would expect, in this phase I study, we brought vial and syringe into the phase I. We do not want to delay initiating a potential phase II-B study, so of course, we will take vial and syringe into that phase II-B study that Sam described. As we think, reflecting on canvuparatide, we did the exact same thing. We took vial and syringe into the phase I. We had in the phase II-A Avail study, vial and syringe.
In October, we initiated our phase III study with the commercial image in that phase III study. We are going to follow that exact same well-trodden path, and make sure that we are ready for a future phase III study with a very commercially reasonable and competitive approach to 4291.
Got it. All right. I cover most of the biotech company in terms of the obesity exposure. It is absolutely possible even to run a phase III by a biotech company. What is your corporate strategy in terms of clinical development and then also commercialization for your obesity franchise, given your broader ability?
Our goal is to deliver data from this phase I and II-A study, and a future II-B study, that clearly demonstrates clinical differentiation for 4291. We believe that value maximization, particularly in obesity, is going to be realized through running concurrent phase III studies, multiple phase III studies, and that that's going to require a partner for us to fully maximize value. That's the approach that we intend to take with 4291, and in fact, with the broader obesity portfolio, because our goal here is to assemble a collection of assets against validated targets in obesity that are differentiated, leveraging the platform. So delivering on true once monthly, achieving a slower rise to Cmax to mitigate GI intolerance.
Good example of this is 6180, our triple G, where we had data, as you know, on Sunday, at ObesityWeek, showing the initial preclinical data and demonstrating in non-human primates our ability to project a dose, which is a monthly dose for 6180. That's the sort of approach that you can expect from us across a range of targets that are now validated in this field, that we'll assemble that group of assets and product candidates to enable a full portfolio, a full complement of medicines that would be administered on a once-monthly basis with that unique PK profile, avoiding the burst effect.
Yeah. It's a pretty clear strategic interest for long-acting obesity franchises, very high. We just came back from ObesityWeek, and we saw quite a few preclinical programs for the long-acting technology. How would you comment on your long-acting technology, which is albumin and then the fatty acid-related, and then for the other ones, maybe in depot and then some of the other technologies? What's the pros and cons you would say, and then why this will be a right approach for obesity franchise? Because we see some of the other ones, and they didn't pan out pretty well in terms of the long-acting.
Yeah, I think it's been certainly a challenge for the field, right? When you look at, gosh, whether it's Novo with their Ascendis collaboration and the termination of that collaboration, trying to achieve a once-monthly sema, and even Pfizer, in fact, with their acquisition of Metsera and having to continue to dose once weekly and not seeming to achieve a true once-monthly profile. The landscape, we think, is pretty wide open in terms of the absence of true once-monthly agents. We think our platform technology and the way we design peptides, we can engineer a release profile that's anywhere from one hour out to 1,000 hours with the platform technology, so out to a full month. That's fundamentally unique. You could argue, even with the blinded data that we showed back in May, that it's now clinically validated in obesity.
We've already validated, by the way, the prodrug technology as it relates to canvuparatide. We do view it as being unique. I'm not aware of any other clinical data, for certain, or even preclinical data that is compelling and shows the ability to take a peptide, engineer it to offer this differentiated PK profile, which then translates into either improved tolerability or true once monthly.
Yeah. Okay, good. All right. Should not be loose on us, and you have a lead program, canvuparatide. You're running phase III, right? It's going to take a little bit of time to get to the readout. But just in terms of any updates from that program, enrollment kind of on track, because you do have a commercial product out there, and then how should we think of the enrollment on time and then the data readout?
Yeah, so we are on track, so it's good news. We disclosed that we will be completing the recruitment by the second half of next year, and as I said, happy to confirm that we will be delivering. We have a very good reason to believe. The enthusiasm from the patients and the investigator has been constant. I mean, they are very, very interested in the weekly administration.
When we went to the hypoPARAthyroidism Association, then we meet with expert, we meet with patient, and all of them share the same interest in even participating to our trial. We had the investigator meeting two months ago in the U.S., and again, great participation, great engagement. Overall, as of today, we haven't seen any impact, or no impact on the YORVIPATH, even on the market, on the recruitment, and on the recruitment timelines. Very confident that we will be on time.
I think what's encouraging, Roger, is speaking of the once-daily injectable competitor, it's very encouraging to see the really rapid uptake of YORVIPATH in the market, right? Ascendis just reported their Q3 results. I think they're on a $1.2 billion or so run rate in terms of revenue, which is very encouraging. We understand that the penetration into the market is probably 5%-7%, so still very early in the growth trajectory in the market. All of this just validates our understanding of the size of the chronic hypoparathyroidism market, the unmet need, the interest from patients and from physicians in having a true replacement therapy. It's a really nice foundation and a nice setup for us as we complete the oPTimize study, which we think we can get to full enrollment of that study in the second half of next year.
It's a really nice setup for us to enter into a market that is already validated as having multi-billion dollar peak revenue potential. We're looking forward to, of course, generating the phase III data, but continuing to advance that program.
Excellent. That's a perfect segue because you have a biotech company, commercialize it very successful. For canvuparatide, what is your commercial strategy? Do you think you need a partner or you can do this by yourself?
This market, the chronic HP market, I think is very well suited to a company our size in terms of our ability to scale a commercial organization in the U.S. in particular, to call on the group of physicians who treat these patients and deliver the information that needs to be delivered to drive utilization and uptake. We brought on board earlier this year our Chief Commercial Officer. We're already starting the pre-commercial work that needs to be done to be ready for a potential future launch, and we're excited about the ability to do that on our own as a standalone company. When you look at the construct of our portfolio, it's pretty unique.
On the one hand, we have canvuparatide in a market that is already credentialed as a multi-billion dollar peak revenue opportunity. On the other hand, you have our broad obesity portfolio that we believe will be fundamentally differentiated. There are two very unique elements, I suppose, to the portfolio, all based on the same platform technology, but multiple ways for us to create value for patients and also for our shareholders.
Excellent. Okay, great. You are running a phase III, and then you potentially can run a phase IIb for your obesity program. Then you are also developing multiple pipeline based on your platform. How is the cash position and the capital allocation, and then how much is funded for your pipeline?
Good question. We are very well financed, so we have over $480 million on the balance sheet as of the end of Q3, and our runway guidance is that that will take us into 2029 and allow us to continue, of course, to advance the phase III program for canvuparatide to make some of the early investments that we need to make from a commercial perspective to be ready for potential future commercialization. That also covers the early-stage obesity portfolio that we have, and very importantly, also will allow us to conduct this phase IIb study that we discussed for 4291. With all of that already accommodated by the runway guidance, we have many opportunities here in the relative near term to demonstrate the value that we intend to create with the cash that we have on the balance sheet today.
Excellent. Okay. Right on time. Anything else you want to touch on that we have not really talked about? I know you mentioned the triple G, which is probably the next wave of the obesity pipeline. Anything else you want to touch on?
Yeah, we do have those two earlier stage assets in the obesity portfolio, which are in IND-enabling studies, and we will continue work in that direction with the potential in the future to nominate additional candidates. But we think we are really well positioned and very excited about the readout coming up here in Q4.
Excellent. All right. Thank you so much, Steve.
Yeah.
Thank you so much.
Thank you, Roger.
Bye. Thank you, everyone.